Merck is forking out $5.85 per share for the California company, a sizeable premium on Immune Design’s share price of around $1.50 in the weeks building up to the deal, and which values it at ...

Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that ...

Merck licenses the protein, called berahyaluronidase alfa, from Alteogen. Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents.

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

NEW YORK, March 27 (Reuters) - Merck & Co (MRK.N), opens new tab said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck has recently achieved a significant milestone with the European Commission's approval of its pneumococcal vaccine CAPVAXIVE®, boosting its portfolio in the vaccines market. Despite this ...

L to R: Zach Cherry, Britt Lower, Adam Scott, Tramell Tillman, Gwendoline Christie and Dan Erickson surprise London commuters on their way to work at a "Severance" installation at the More London ...

Merck (MRK), known as MSD outside of the United States and Canada, announced that the European Commission, or EC, has approved CAPVAXIVE, or Pneumococcal 21-valent Conjugate Vaccine, for active ...

Astrophysicist Dr. Paul Sutter spoke with NBC News' Gadi Schwartz on the spectacular atmospheric event that a SpaceX rocket created over the European sky. March 26, 2025 ...

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the latest in a series of cross-border deals between Western ...